IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees

While the RV144 HIV vaccine trial led to moderately reduced risk of HIV acquisition, emerging data from the HVTN702 trial point to the critical need to reexamine RV144-based correlates of reduced risk of protection. While in RV144, the induction of V2-binding, non-IgA, IgG3 antibody responses with n...

Full description

Bibliographic Details
Main Authors: Stephanie Fischinger, Sepideh Dolatshahi, Madeleine F. Jennewein, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Nelson Michael, Sandhya Vasan, Margaret E. Ackerman, Hendrik Streeck, Galit Alter
Format: Article
Language:English
Published: American Society for Clinical investigation 2020-11-01
Series:JCI Insight
Subjects:
AIDS/HIV
Vaccines
Online Access:https://doi.org/10.1172/jci.insight.140925

Internet

https://doi.org/10.1172/jci.insight.140925

Similar Items